Vericel (VCEL) Receivables (2010 - 2026)
Vericel (VCEL) reported Receivables of $72.4 million for Q1 2026, up 36.83% on a YoY basis from $52.9 million in Q1 2025, and down 14.48% sequentially from $84.6 million in Q4 2025.
Vericel (VCEL) Receivables (2010 - 2026) Analysis & Trends
Vericel (VCEL) has 17 years of Receivables data on file, last reported at $72.4 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables rose 36.83% year-over-year to $72.4 million; the trailing twelve-month figure through Mar 2026 stood at $72.4 million (up 36.83% YoY), and the FY2025 full-year result was $84.6 million, up 37.9% from the prior year.
- Receivables eased to $72.4 million in Q1 2026, from $84.6 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $84.6 million in Q4 2025 to a low of $31.9 million in Q1 2022.
- A 5-year average of $50.8 million and a median of $48.5 million in 2024 frame the typical range for Receivables.
- Across the five-year window, Receivables climbed 5.17% in 2024 and surged 37.9% in 2025, its largest moves.
- Tracing VCEL's Receivables over 5 years: stood at $46.5 million in 2022, then climbed by 25.39% to $58.4 million in 2023, then grew by 5.17% to $61.4 million in 2024, then jumped by 37.9% to $84.6 million in 2025, then dropped by 14.48% to $72.4 million in 2026.
- Business Quant data shows VCEL's Receivables at $72.4 million in Q1 2026, $84.6 million in Q4 2025, and $60.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Vericel | 2.30 Bn | 2.15 Bn | 49.27 Mn | 72.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72.38 Mn |
| Dec 31, 2025 | 84.63 Mn |
| Sep 30, 2025 | 60.43 Mn |
| Jun 30, 2025 | 64.29 Mn |
| Mar 31, 2025 | 52.90 Mn |
| Dec 31, 2024 | 61.38 Mn |
| Sep 30, 2024 | 48.48 Mn |
| Jun 30, 2024 | 48.00 Mn |
| Mar 31, 2024 | 49.93 Mn |
| Dec 31, 2023 | 58.36 Mn |
| Sep 30, 2023 | 39.73 Mn |
| Jun 30, 2023 | 38.32 Mn |
| Mar 31, 2023 | 38.36 Mn |
| Dec 31, 2022 | 46.54 Mn |
| Sep 30, 2022 | 34.30 Mn |
| Jun 30, 2022 | 33.66 Mn |
| Mar 31, 2022 | 31.86 Mn |
| Dec 31, 2021 | 37.44 Mn |
| Sep 30, 2021 | 28.91 Mn |
| Jun 30, 2021 | 31.73 Mn |